Login to Your Account

Clinic Roundup

Tuesday, February 12, 2013

• Catabasis Pharmaceuticals Inc., of Cambridge, Mass., said a three-part series of Phase I studies showed that CAT-1004, a SMART Linker conjugate of docosahexaenoic acid (DHA) and salicylate created using the company's technology, was safe and well tolerated. Data also showed that the conjugated compound was absorbed following oral administration and metabolized to its active components intracellularly, providing proof of concept for the SMART Linker platform.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription